The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Atherectomy

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Atherectomy

  • Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence [1].
  • Women undergoing atherectomy who received estrogen had a significantly lower late loss index (0.06 vs. -0.63, p = 0.002), less late loss (0.06 vs. -0.61 mm, p = 0.0006), larger minimal lumen diameter (p = 0.044) and lower restenosis rates (p = 0.038 for > 50% stenosis) than those not using estrogen [2].
  • OBJECTIVES: We sought to determine the effects of platelet glycoprotein IIb/IIIa receptor blockade on adverse outcomes, especially non-Q wave myocardial infarction, in patients undergoing directional atherectomy in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial [3].
  • Is all unstable angina the same? insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). The CAVEAT-Investigators [4].
  • Rather, reduction in the probability of late restenosis appears to be most directly related to the ability of directional atherectomy to provide the largest acute luminal diameter safely possible, thus providing better tolerance of subsequent intimal hyperplasia before hemodynamically significant renarrowing results at the treatment site [5].
 

High impact information on Atherectomy

  • RESULTS: After atherectomy, the mean (+/- SD) minimal luminal diameter of the target vessel was greater in the 49 patients who were seropositive for CMV than in the 26 patients who were seronegative (3.18 +/- 0.51 mm vs. 2.89 +/- 0.45 mm, P=0.01) [6].
  • We conclude that the expression of the B isoform of nonmuscle myosin heavy chain is increased in some coronary atherosclerotic plaques and that this increase in expression identifies a group of lesions at high risk for restenosis after atherectomy [7].
  • 8-epi PGF2alpha ranged from 1.310-3.450 pmol/micromol phospholipid in atherectomy specimens compared with 0.045-0.115 pmol/micromol phospholipid (P < 0.001) in vascular tissue devoid of atherosclerosis [8].
  • 37 atherosclerotic lesions (18 primary and 19 restenotic) retrieved by directional atherectomy from either coronary or peripheral arteries were then studied for the expression of PCNA, using in situ hybridization or immunohistochemistry [9].
  • Substantially more PAI-1 and substantially less u-PA were present in the atherectomy samples from subjects with diabetes [1].
 

Chemical compound and disease context of Atherectomy

 

Biological context of Atherectomy

 

Anatomical context of Atherectomy

 

Associations of Atherectomy with chemical compounds

  • One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I) [21].
  • OBJECTIVES: The intravascular ultrasound (IVUS) substudy of OARS (Optimal Atherectomy Restenosis Study) was designed to assess the mechanisms of restenosis after directional coronary atherectomy (DCA) [22].
  • CONCLUSIONS: This study demonstrates the potential for estrogen replacement therapy to reduce angiographic measures of restenosis in postmenopausal women after coronary intervention, particularly in those undergoing atherectomy [2].
  • METHODS: Serial myocardial enzyme determinations were performed on 2,099 patients who underwent angioplasty or atherectomy in the Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications (EPIC) trial [23].
  • Effects of intracoronary nitroglycerin on lumen diameter during early follow-up angiography after coronary excimer laser atherectomy [24].
 

Gene context of Atherectomy

 

Analytical, diagnostic and therapeutic context of Atherectomy

  • Comparison of coronary luminal quantification obtained from intracoronary ultrasound and both geometric and videodensitometric quantitative angiography before and after balloon angioplasty and directional atherectomy [30].
  • The minimal luminal diameter of each lesion was measured before and immediately after intervention in 102 single Palmaz-Schatz stents and 134 directional atherectomies, 192 (81%) of which had repeat angiographic measurement of minimal luminal diameter 6 months after the intervention [31].
  • Primary treatment for these SVG was performed in the following manner; PTCA 29, intragraft urokinase 12, TEC atherectomy 39 [32].
  • The authors applied PCR to detect platelet-derived growth factor-A mRNA expression in 12 human lesions sampled percutaneously by directional atherectomy [15].
  • METHODS AND RESULTS: We retrieved tissue specimens from patients with symptomatic in-stent restenosis using a novel helix cutter atherectomy device. cDNA samples prepared from neointima (n=10) and, as a control, from the media of normal arteries (n=14) were amplified using a novel polymerase chain reaction protocol and hybridized to cDNA arrays [33].

References

  1. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Sobel, B.E., Woodcock-Mitchell, J., Schneider, D.J., Holt, R.E., Marutsuka, K., Gold, H. Circulation (1998) [Pubmed]
  2. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. O'Brien, J.E., Peterson, E.D., Keeler, G.P., Berdan, L.G., Ohman, E.M., Faxon, D.P., Jacobs, A.K., Topol, E.J., Califf, R.M. J. Am. Coll. Cardiol. (1996) [Pubmed]
  3. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. Lefkovits, J., Blankenship, J.C., Anderson, K.M., Stoner, G.L., Talley, J.D., Worley, S.J., Weisman, H.F., Califf, R.M., Topol, E.J. J. Am. Coll. Cardiol. (1996) [Pubmed]
  4. Is all unstable angina the same? insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). The CAVEAT-Investigators. Harrington, R.A., Califf, R.M., Holmes, D.R., Pieper, K.S., Lincoff, A.M., Berdan, L.G., Thompson, T.D., Topol, E.J. Am. Heart J. (1999) [Pubmed]
  5. Directional coronary atherectomy: how much lumen enlargement is optimal? Baim, D.S., Kuntz, R.E. Am. J. Cardiol. (1993) [Pubmed]
  6. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. Zhou, Y.F., Leon, M.B., Waclawiw, M.A., Popma, J.J., Yu, Z.X., Finkel, T., Epstein, S.E. N. Engl. J. Med. (1996) [Pubmed]
  7. Relation between activated smooth-muscle cells in coronary-artery lesions and restenosis after atherectomy. Simons, M., Leclerc, G., Safian, R.D., Isner, J.M., Weir, L., Baim, D.S. N. Engl. J. Med. (1993) [Pubmed]
  8. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. Praticò, D., Iuliano, L., Mauriello, A., Spagnoli, L., Lawson, J.A., Rokach, J., Maclouf, J., Violi, F., FitzGerald, G.A. J. Clin. Invest. (1997) [Pubmed]
  9. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. Pickering, J.G., Weir, L., Jekanowski, J., Kearney, M.A., Isner, J.M. J. Clin. Invest. (1993) [Pubmed]
  10. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Gibson, C.M., Goel, M., Cohen, D.J., Piana, R.N., Deckelbaum, L.I., Harris, K.E., King, S.B. J. Am. Coll. Cardiol. (1998) [Pubmed]
  11. Blue toe syndrome: treatment with percutaneous atherectomy. Dolmatch, B.L., Rholl, K.S., Moskowitz, L.B., Dake, M.D., van Breda, A., Kaplan, J.O., Katzen, B.T. Radiology. (1989) [Pubmed]
  12. Directional coronary atherectomy: the Vienna experience. Kiss, K., Hirschl, M.M., Wexberg, P., Hassan, A., Steurer, G., Glogar, D. Journal of interventional cardiology. (2001) [Pubmed]
  13. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Schieffer, B., Schieffer, E., Hilfiker-Kleiner, D., Hilfiker, A., Kovanen, P.T., Kaartinen, M., Nussberger, J., Harringer, W., Drexler, H. Circulation (2000) [Pubmed]
  14. The alpha-1 adrenergic blocking agent urapidil counteracts postrotational atherectomy "elastic recoil" where nitrates have failed. Gregorini, L., Marco, J., Bernies, M., Cassagneau, B., Pomidossi, G., Anguissola, G.B., Fajadet, J. Am. J. Cardiol. (1997) [Pubmed]
  15. Quantitative polymerase chain reaction (PCR) to analyze messenger-RNA expression in tissue obtained by directional atherectomy. Köster, R., Windstetter, U., Gulizia, J.M., Uberfuhr, P., Baumann, G., Höfling, B. Angiology. (1994) [Pubmed]
  16. Induction of hyaluronic acid synthase 2 (HAS2) in human vascular smooth muscle cells by vasodilatory prostaglandins. Sussmann, M., Sarbia, M., Meyer-Kirchrath, J., Nüsing, R.M., Schrör, K., Fischer, J.W. Circ. Res. (2004) [Pubmed]
  17. Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism. De Palma, R., Del Galdo, F., Abbate, G., Chiariello, M., Calabró, R., Forte, L., Cimmino, G., Papa, M.F., Russo, M.G., Ambrosio, G., Giombolini, C., Tritto, I., Notaristefano, S., Berrino, L., Rossi, F., Golino, P. Circulation (2006) [Pubmed]
  18. Sheath introducer technique for recanalizing total occlusions of the superficial femoral artery. Bauriedel, G., DeMaio, S.J., Höfling, B. Catheterization and cardiovascular diagnosis. (1992) [Pubmed]
  19. The use of endothelial seeding of prosthetic arterial bypass grafts. Herring, M.B. Surgery annual. (1991) [Pubmed]
  20. Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis and its regulation by angiotensin II. Hilfiker, A., Hilfiker-Kleiner, D., Fuchs, M., Kaminski, K., Lichtenberg, A., Rothkötter, H.J., Schieffer, B., Drexler, H. Circulation (2002) [Pubmed]
  21. One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I). Elliott, J.M., Berdan, L.G., Holmes, D.R., Isner, J.M., King, S.B., Keeler, G.P., Kearney, M., Califf, R.M., Topol, E.J. Circulation (1995) [Pubmed]
  22. Remodeling after directional coronary atherectomy (with and without adjunct percutaneous transluminal coronary angioplasty): a serial angiographic and intravascular ultrasound analysis from the Optimal Atherectomy Restenosis Study. Lansky, A.J., Mintz, G.S., Popma, J.J., Pichard, A.D., Kent, K.M., Satler, L.F., Baim, D.S., Kuntz, R.E., Simonton, C., Bersin, R.M., Hinohara, T., Fitzgerald, P.J., Leon, M.B. J. Am. Coll. Cardiol. (1998) [Pubmed]
  23. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Narins, C.R., Miller, D.P., Califf, R.M., Topol, E.J. J. Am. Coll. Cardiol. (1999) [Pubmed]
  24. Effects of intracoronary nitroglycerin on lumen diameter during early follow-up angiography after coronary excimer laser atherectomy. Baumbach, A., Haase, K.K., Voelker, W., Mauser, M., Karsch, K.R. Eur. Heart J. (1991) [Pubmed]
  25. Growth factors released into the coronary circulation after vascular injury promote proliferation of human vascular smooth muscle cells in culture. Caplice, N.M., Aroney, C.N., Bett, J.H., Cameron, J., Campbell, J.H., Hoffmann, N., McEniery, P.T., West, M.J. J. Am. Coll. Cardiol. (1997) [Pubmed]
  26. Expression of IGF-I, IGF-I receptor and IGF binding proteins-1, -2, -3, -4 and -5 in human atherectomy specimens. Grant, M.B., Wargovich, T.J., Ellis, E.A., Tarnuzzer, R., Caballero, S., Estes, K., Rossing, M., Spoerri, P.E., Pepine, C. Regul. Pept. (1996) [Pubmed]
  27. C-Type natriuretic peptide and natriuretic peptide receptors are expressed by smooth muscle cells in the neointima after percutaneous coronary intervention. Naruko, T., Itoh, A., Haze, K., Ehara, S., Fukushima, H., Sugama, Y., Shirai, N., Ikura, Y., Ohsawa, M., Ueda, M. Atherosclerosis (2005) [Pubmed]
  28. Regulated expression of the BTEB2 transcription factor in vascular smooth muscle cells: analysis of developmental and pathological expression profiles shows implications as a predictive factor for restenosis. Hoshino, Y., Kurabayashi, M., Kanda, T., Hasegawa, A., Sakamoto, H., Okamoto, E., Kowase, K., Watanabe, N., Manabe, I., Suzuki, T., Nakano, A., Takase, S., Wilcox, J.N., Nagai, R. Circulation (2000) [Pubmed]
  29. Increased expression of monocyte chemoattractant protein-1 in atherectomy specimens from patients with restenosis after percutaneous transluminal coronary angioplasty. Hokimoto, S., Oike, Y., Saito, T., Kitaoka, M., Oshima, S., Noda, K., Moriyama, Y., Ishibashi, F., Ogawa, H. Circ. J. (2002) [Pubmed]
  30. Comparison of coronary luminal quantification obtained from intracoronary ultrasound and both geometric and videodensitometric quantitative angiography before and after balloon angioplasty and directional atherectomy. Ozaki, Y., Violaris, A.G., Kobayashi, T., Keane, D., Camenzind, E., Di Mario, C., de Feyter, P., Roelandt, J.R., Serruys, P.W. Circulation (1997) [Pubmed]
  31. The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting. Kuntz, R.E., Safian, R.D., Carrozza, J.P., Fishman, R.F., Mansour, M., Baim, D.S. Circulation (1992) [Pubmed]
  32. PTCA, thrombolysis or atherectomy: rational treatment of recently occluded saphenous vein grafts. Mehta, S., Margolis, J.R., Moore, L., Pena, R. Indian heart journal. (1995) [Pubmed]
  33. Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation. Zohlnhöfer, D., Klein, C.A., Richter, T., Brandl, R., Murr, A., Nührenberg, T., Schömig, A., Baeuerle, P.A., Neumann, F.J. Circulation (2001) [Pubmed]
 
WikiGenes - Universities